Crispr Therapeutics shares tumble after significant earnings miss
LONDON - HSQ Investment Limited has nearly completed its acquisition of Kingswood Holdings Limited, with 99.27% of Kingswood’s shares either owned or under valid acceptances as of April 15, 2025, the company announced Wednesday. The unconditional cash offer by HSQ, made public on March 18, 2025, priced Kingswood’s shares at 7 pence each.
As the last day of trading on AIM for Kingswood’s shares was Wednesday, the company is set to be delisted and will re-register as a private limited entity. This development follows the receipt of acceptances for approximately 9.88% of Kingswood’s issued share capital, adding to the 89.39% of shares already held by HSQ.
The Offer, which was detailed in documents sent to Kingswood shareholders on March 25, 2025, remains open for acceptance. Kingswood’s Independent (LON:IOG) Directors have recommended that shareholders accept the Offer, which is not contingent on a minimum acceptance level.
Shareholders who have yet to accept the Offer are urged to do so promptly, with the procedure outlined in the Offer Document. Those holding shares in uncertificated form must submit their acceptance through CREST, and those with certificated shares should return the completed Form of Acceptance and any relevant documents of title.
The Offer Document, available on the websites of both HSQ and Kingswood, provides comprehensive information on the acquisition process. Shareholders who accepted the Offer by April 15 will receive their due consideration by April 29, 2025. Any acceptances received after this date will be processed within 14 calendar days.
HSQ and its Directors, as well as any parties acting in concert with them, have not engaged in any borrowing or lending of Kingswood securities, nor do they hold any short positions in relation to Kingswood’s shares, as of the latest announcement.
This news is based on a press release statement from HSQ Investment Limited.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.